Abstract
Background: Aberrant expression of eukaryotic translation initiation factor 4E (eIF4E) is common in many types of cancer including acute myeloid leukaemia (AML). Phosphorylation of eIF4E by MAPK-interacting kinases (Mnks) is essential for the eIF4E-mediated oncogenic activity. As such, the pharmacological inhibition of Mnks can be an effective strategy for the treatment of cancer.
Methods: A series of N-phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine derivatives was designed and synthesised. The Mnk inhibitory activity of these derivatives as well as their anti-proliferative activity against MV4-11 AML cells was determined.
Results: These compounds were identified as potent Mnk2 inhibitors. Most of them demonstrated potent anti-proliferative activity against MV4-11 AML cells. The cellular mechanistic studies of the representative inhibitors revealed that they reduced the level of phosphorylated eIF4E and induced apoptosis by down-regulating the anti-apoptotic protein myeloid cell leukaemia 1 (Mcl-1) and by cleaving poly(ADP-ribose)polymerase (PARP). The lead compound 7k possessed desirable pharmacokinetic properties and oral bioavailability.
Conclusion: This work proposes that exploration of the structural diversity in the context of Nphenyl- 4-(1H-pyrrol-3-yl)pyrimidin-2-amine would offer potent and selective Mnk inhibitors.
Keywords: Mnk, eIF4E, inhibitor, structure-activity relationship, N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine, antileukaemia.
Graphical Abstract
[1]
Waskiewicz, A.J.; Flynn, A.; Proud, C.G.; Cooper, J.A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J., 1997, 16, 1909-1920.
[2]
Cargnello, M.; Roux, P.P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev., 2011, 75, 50-83.
[3]
O’Loghlen, A.; González, V.M.; Salinas, M.; Elena Martín, M. Suppression of human Mnk1 by small interfering RNA increases the eukaryotic initiation factor 4F activity in HEK293T cells. FEBS Lett., 2004, 578, 31-35.
[4]
Maimon, A.; Mogilevsky, M.; Shilo, A.; Golan-Gerstl, R.; Obiedat, A.; Ben-Hur, V.; Lebenthal-Loinger, I.; Stein, I.; Reich, R.; Beenstock, J.; Zehorai, E. Andersen, Claus L.; Thorsen, K.; Ørntoft, Torben F.; Davis, Roger J.; Davidson, B.; Mu, D.; Karni, R. Mnk2 alternative splicing modulates the p38-MAPK pathway and ompacts Ras-induced transformation. Cell Rep., 2014, 7, 501-513.
[5]
Fukunaga, R.; Hunter, T. MNK1, a new MAP kinase‐activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J., 1997, 16, 1921-1933.
[6]
Korneeva, N.L.; Song, A.; Gram, H.; Edens, M.A.; Rhoads, R.E. Inhibition of MAP kinase-interacting kinase (MNK) preferentially affects translation of mRNAs containing both a 5′-terminal cap and hairpin. J. Biol. Chem., 2015, 291, 3455-3467.
[7]
Buxade, M.; Parra-Palau, J.L.; Proud, C.G. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front. Biosci., 2008, 13, 5359-5373.
[8]
Joshi, S.; Platanias, L.C. Mnk kinase pathway: Cellular functions and biological outcomes. World J. Biol. Chem., 2014, 5, 321-333.
[9]
Hou, J.; Lam, F.; Proud, C.G.; Wang, S. Targeting Mnks for cancer therapy. Oncotarget, 2012, 3, 118-131.
[10]
Diab, S.; Kumarasiri, M.; Yu, M.; Teo, T.; Proud, C.G.; Milne, R.; Wang, S. MAP kinase-interacting kinases - Emerging targets against cancer. Chem. Biol., 2014, 21, 441-452.
[11]
Lim, S.; Saw, T.Y.; Zhang, M.; Janes, M.R.; Nacro, K.; Hill, J.; Lim, A.Q.; Chang, C.T.; Fruman, D.A.; Rizzieri, D.A.; Tan, S.Y.; Fan, H.; Chuah, C.T.; Ong, S.T. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc. Natl. Acad. Sci. USA, 2013, 110, E2298-E2307.
[12]
Bianchini, A.; Loiarro, M.; Bielli, P.; Busa, R.; Paronetto, M.P.; Loreni, F.; Geremia, R.; Sette, C. Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis, 2008, 29, 2279-2288.
[13]
Zheng, J.; Li, J.; Xu, L.; Xie, G.; Wen, Q.; Luo, J.; Li, D.; Huang, D.; Fan, S. Phosphorylated Mnk1 and eIF4E are associated with lymph node metastasis and poor prognosis of nasopharyngeal carcinoma. PLoS One, 2014, 9, 89220-89228.
[14]
Flynn, A.; Proud, C.G. Serine 209, not serine 53, is the major site of phosphorylation in initiation factor eIF-4E in serum-treated Chinese hamster ovary cells. J. Biol. Chem., 1995, 270, 21684-21688.
[15]
Joshi, B.; Cai, A.L.; Keiper, B.D.; Minich, W.B.; Mendez, R.; Beach, C.M.; Stepinski, J.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R.E. Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J. Biol. Chem., 1995, 270, 14597-14603.
[16]
Duncan, R.; Milburn, S.C.; Hershey, J.W. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J. Biol. Chem., 1987, 262, 380-388.
[17]
Gingras, A.C.; Raught, B.; Sonenberg, N. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem., 1999, 68, 913-963.
[18]
Rhoads, R.E. Cap recognition and the entry of mRNA into the protein synthesis initiation cycle. Trends Biochem. Sci., 1988, 13, 52-56.
[19]
Bhat, M.; Robichaud, N.; Hulea, L.; Sonenberg, N.; Pelletier, J.; Topisirovic, I. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov., 2015, 14, 261-278.
[20]
Adesso, L.; Calabretta, S.; Barbagallo, F.; Capurso, G.; Pilozzi, E.; Geremia, R.; Delle Fave, G.; Sette, C. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene, 2013, 32, 2848-2857.
[21]
Fan, S.; Ramalingam, S.S.; Kauh, J.; Xu, Z.; Khuri, F.R.; Sun, S-Y. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol. Ther., 2009, 8, 1463-1469.
[22]
Liang, S.; Guo, R.; Zhang, Z.; Liu, D.; Xu, H.; Xu, Z.; Wang, X.; Yang, L. Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth. Oncol. Rep., 2013, 29, 2422-2430.
[23]
Proud, C.G. Mnks, eIF4E phosphorylation and cancer. Biochim. Biophys. Acta, 2014, 1849, 766-773.
[24]
Han, M.; Wang, W.; Wang, L.; Jiang, Y. Expression of eukaryotic initiation factor 4 E in hypopharyngeal carcinoma. J. Int. Med. Res., 2014, 42, 976-983.
[25]
Bramham, C.R.; Jensen, K.B.; Proud, C.G. Tuning specific translation in cancer metastasis and synaptic memory: Control at the MNK–eIF4E axis. Trends Biochem. Sci., 2016, 41, 847-858.
[26]
Ueda, T.; Watanabe-Fukunaga, R.; Fukuyama, H.; Nagata, S.; Fukunaga, R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol. Cell. Biol., 2004, 24, 6539-6549.
[27]
Ueda, T.; Sasaki, M.; Elia, A.J. Chio, II; Hamada, K.; Fukunaga, R.; Mak, T.W. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc. Natl. Acad. Sci. USA, 2010, 107, 13984-13990.
[28]
Furic, L.; Rong, L.; Larsson, O.; Koumakpayi, I.H.; Yoshida, K.; Brueschke, A.; Petroulakis, E.; Robichaud, N.; Pollak, M.; Gaboury, L.A.; Pandolfi, P.P.; Saad, F.; Sonenberg, N. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl. Acad. Sci. USA, 2010, 107, 14134-14139.
[29]
Wendel, H.G.; Silva, R.L.; Malina, A.; Mills, J.R.; Zhu, H.; Ueda, T.; Watanabe-Fukunaga, R.; Fukunaga, R.; Teruya-Feldstein, J.; Pelletier, J.; Lowe, S.W. Dissecting eIF4E action in tumorigenesis. Genes Dev., 2007, 21, 3232-3237.
[30]
Santag, S.; Siegel, F.; Wengner, A.M.; Lange, C.; Bömer, U.; Eis, K.; Pühler, F.; Lienau, P.; Bergemann, L.; Michels, M.; von Nussbaum, F.; Mumberg, D.; Petersen, K. BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity. Cancer Lett., 2017, 390, 21-29.
[31]
Webster, K.R.; Goel, V.K.; Hung, I.N.; Parker, G.S.; Staunton, J.; Neal, M.; Molter, J.; Chiang, G.G.; Jessen, K.A.; Wegerski, C.J.; Sperry, S.; Huang, V.; Chen, J.; Thompson, P.A.; Appleman, J.R.; Webber, S.E.; Sprengeler, P.A.; Reich, S.H. eFT508, a potent and selective mitogen-activated protein kinase interacting kinase (MNK) 1 and 2 inhibitor, is efficacious in preclinical models of diffuse large B-cell lymphoma (DLBCL). Blood, 2015, 126, 1554-1554.
[32]
Reich, S.H.; Sprengeler, P.A.; Chiang, G.G.; Appleman, J.R.; Chen, J.; Clarine, J.; Eam, B.; Ernst, J.T.; Han, Q.; Goel, V.K.; Han, E.Z.R.; Huang, V.; Hung, I.N.J.; Jemison, A.; Jessen, K.A.; Molter, J.; Murphy, D.; Neal, M.; Parker, G.S.; Shaghafi, M.; Sperry, S.; Staunton, J.; Stumpf, C.R.; Thompson, P.A.; Tran, C.; Webber, S.E.; Wegerski, C.J.; Zheng, H.; Webster, K.R. Structure-based design of pyridone-aminal eFT508 targeting dysregulated translation by selective mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2) inhibition. J. Med. Chem., 2018, 61, 3516-3540.
[33]
Lineham, E.; Spencer, J.; Morley, S.J. Dual abrogation of MNK and mTOR: A novel therapeutic approach for the treatment of aggressive cancers. Future Med. Chem., 2017, 9, 1539-1555.
[34]
Li, P.; Diab, S.; Yu, M.; Adams, J.; Islam, S.; Basnet, S.K.; Albrecht, H.; Milne, R.; Wang, S. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Oncotarget, 2016, 7, 56811-56825.
[35]
Diab, S.; Abdelaziz, A.M.; Li, P.; Teo, T.; Basnet, S.K.; Noll, B.; Rahaman, M.H.; Lu, J.; Hou, J.; Yu, M.; Le, B.T.; Albrecht, H.; Milne, R.W.; Wang, S. Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia. Eur. J. Med. Chem., 2017, 139, 762-772.
[36]
Diab, S.; Teo, T.; Kumarasiri, M.; Li, P.; Yu, M.; Lam, F.; Basnet, S.K.; Sykes, M.J.; Albrecht, H.; Milne, R.; Wang, S. Discovery of 5-(2-(phenylamino) pyrimidin-4-yl) thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: Synthesis, SAR analysis and biological evaluation. ChemMedChem, 2014, 9, 962-972.
[37]
Kumarasiri, M.; Teo, T.; Wang, S. Dynamical insights of Mnk2 kinase activation by phosphorylation to facilitate inhibitor discovery. Future Med. Chem., 2015, 7, 91-102.
[38]
Teo, T.; Yang, Y.; Yu, M.; Basnet, S.K.; Gillam, T.; Hou, J.; Schmid, R.M.; Kumarasiri, M.; Diab, S.; Albrecht, H.; Sykes, M.J.; Wang, S. An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis. Eur. J. Med. Chem., 2015, 103, 539-550.
[39]
Yu, M.; Li, P.; Basnet, S.K.; Kumarasiri, M.; Diab, S.; Teo, T.; Albrecht, H.; Wang, S. Discovery of 4-(dihydropyridinon-3-yl) amino-5-methylthieno[2,3-d] pyrimidine derivatives as potent Mnk inhibitors: Synthesis, structure-activity relationship analysis and biological evaluation. Eur. J. Med. Chem., 2015, 95, 116-126.
[40]
Basnet, S.K.; Diab, S.; Schmid, R.; Yu, M.; Yang, Y.; Gillam, T.A.; Teo, T.; Li, P.; Peat, T.; Albrecht, H.; Wang, S. Identification of a highly conserved allosteric binding site on Mnk1 and Mnk2. Mol. Pharmacol., 2015, 88, 935-948.
[41]
Diab, S.; Li, P.; Basnet, S.K.; Lu, J.; Yu, M.; Albrecht, H.; Milne, R.W.; Wang, S. Unveiling new chemical scaffolds as Mnk inhibitors. Future Med. Chem., 2016, 8, 271-285.
[42]
Teo, T.; Lam, F.; Yu, M.; Yang, Y.; Basnet, S.K.; Albrecht, H.; Sykes, M.J.; Wang, S. Pharmacologic inhibition of MNKs in acute myeloid leukemia. Mol. Pharmacol., 2015, 88, 380-389.
[43]
Altman, J.K.; Szilard, A.; Konicek, B.W.; Iversen, P.W.; Kroczynska, B.; Glaser, H.; Sassano, A.; Vakana, E.; Graff, J.R.; Platanias, L.C. Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood, 2013, 121, 3675-3681.
[44]
Agnieszka, D.; Maciej, M.; Mariusz, M.; Charles-Henry, F.; Krzysztof, B.; Tomasz, R. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: Recent progress in the development of MNK inhibitors. Curr. Med. Chem., 2017, 24, 1-28.
[45]
Falchook, G.S.; Infante, J.R.; Meric-Bernstam, F.; Miller, L.L.; Morison, K.; Vallner, D.; Sperry, S.; Goel, V.; Chiang, G.G.; Webster, K.; Barton, J.; Patel, M.R. A phase 1 dose escalation study of eFT508, an inhibitor of mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK-1) and MNK-2 in patients with advanced solid tumors. J. Clin. Oncol., 2017, 35, 2579-2579.
[46]
Matsui, Y.; Yasumatsu, I.; Yoshida, K.I.; Iimura, S.; Ikeno, Y.; Nawano, T.; Fukano, H.; Ubukata, O.; Hanzawa, H.; Tanzawa, F.; Isoyama, T. A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1. Acta Crystallogr. F Struct. Biol. Commun., 2018, 74, 156-160.
[47]
Hole, A.J.; Baumli, S.; Shao, H.; Shi, S.; Huang, S.; Pepper, C.; Fischer, P.M.; Wang, S.; Endicott, J.A.; Noble, M.E. Comparative structural and functional studies of 4-(Thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity. J. Med. Chem., 2013, 56, 660-670.
[48]
Wang, S.; Midgley, C.A.; Scaërou, F.; Grabarek, J.B.; Griffiths, G.; Jackson, W.; Kontopidis, G.; McClue, S.J.; McInnes, C.; Meades, C.; Mezna, M.; Plater, A.; Stuart, I.; Thomas, M.P.; Wood, G.; Clarke, R.G.; Blake, D.G.; Zheleva, D.I.; Lane, D.P.; Jackson, R.C.; Glover, D.M.; Fischer, P.M. Discovery of N-phenyl-4-(thiazol-5-yl) pyrimidin-2-amine Aurora kinase inhibitors. J. Med. Chem., 2010, 53, 4367-4378.
[49]
Lukasik, P.M.; Elabar, S.; Lam, F.; Shao, H.; Liu, X.; Abbas, A.Y.; Wang, S. Synthesis and biological evaluation of imidazo[4,5-b] pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents. Eur. J. Med. Chem., 2012, 57, 311-322.
[50]
Wang, S.; Wood, G.; Meades, C.; Griffiths, G.; Midgley, C.; McNae, I.; McInnes, C.; Anderson, S.; Jackson, W.; Mezna, M.; Yuill, R.; Walkinshaw, M.; Fischer, P.M. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 4237-4240.
[51]
Lam, F.; Abbas, A.Y.; Shao, H.; Teo, T.; Adams, J.; Li, P.; Bradshaw, T.D.; Fischer, P.M.; Walsby, E.; Pepper, C.; Chen, Y.; Ding, J.; Wang, S. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget, 2014, 5, 7691-7704.
[54]
Kondal Reddy, K.; Subba Rao, N.V. Alkylation and aralkylation of N-heterocycles. Proc. Indiana Acad. Sci., 1969, 70, 81-88.
[56]
Bredereck, H.; Effenberger, F.; Botsch, H. Acid amide reactions. XLV. Reactivity of formamidines, dimethylformamide diethyl acetal (amide acetal), and bis (dimethylamino) methoxymethane (aminal ester). Chem. Ber., 1964, 97, 3397-3406.
[57]
Topisirovic, I.; Guzman, M.L.; McConnell, M.J.; Licht, J.D.; Culjkovic, B.; Neering, S.J.; Jordan, C.T.; Borden, K.L. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol. Cell. Biol., 2003, 23, 8992-9002.
[58]
Assouline, S.; Culjkovic, B.; Cocolakis, E.; Rousseau, C.; Beslu, N.; Amri, A.; Caplan, S.; Leber, B.; Roy, D.C.; Miller, W.H., Jr; Borden, K.L. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): A proof-of-principle clinical trial with ribavirin. Blood, 2009, 114, 257-260.
[59]
Platanias, L.C. Map kinase signaling pathways and hematologic malignancies. Blood, 2003, 101, 4667-4679.
[60]
Reynolds, C.H. Ligand efficiency metrics: Why all the fuss? Future Med. Chem., 2015, 7, 1363-1365.
[61]
Kuntz, I.D.; Chen, K.; Sharp, K.A.; Kollman, P.A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA, 1999, 96, 9997-10002.
[62]
Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S-Y.; McInnes, C.; Zheleva, D.; Walkinshaw, M.D.; Fischer, P.M. 2-Anilino-4-(thiazol-5-yl) pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray crystallography, and biological activity. J. Med. Chem., 2004, 47, 1662-1675.
[63]
Wang, S.; Griffiths, G.; Midgley, C.A.; Barnett, A.L.; Cooper, M.; Grabarek, J.; Ingram, L.; Jackson, W.; Kontopidis, G.; McClue, S.J.; McInnes, C.; McLachlan, J.; Meades, C.; Mezna, M.; Stuart, I.; Thomas, M.P.; Zheleva, D.I.; Lane, D.P.; Jackson, R.C.; Glover, D.M.; Blake, D.G.; Fischer, P.M. Discovery and characterization of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem. Biol., 2010, 17, 1111-1121.
[64]
Shao, H.; Shi, S.; Huang, S.; Hole, A.J.; Abbas, A.Y.; Baumli, S.; Liu, X.; Lam, F.; Foley, D.W.; Fischer, P.M.; Noble, M.; Endicott, J.A.; Pepper, C.; Wang, S. Substituted 4-(thiazol-5-yl)-2-(phenylamino) pyrimidines are highly active CDK9 Inhibitors: Synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. J. Med. Chem., 2013, 56, 640-659.
[65]
Hou, J.; Teo, T.; Sykes, M.J.; Wang, S. Insights into the importance of DFD-motif and insertion I1 in stabilizing the DFD-out conformation of Mnk2 kinase. ACS Med. Chem. Lett., 2013, 4, 736-741.
[66]
Dai, Y.; Dent, P.; Grant, S. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A. Cell Cycle, 2002, 1, 143-152.
[67]
Radomska, H.S.; Alberich-Jordà, M.; Will, B.; Gonzalez, D.; Delwel, R.; Tenen, D.G. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα. J. Clin. Invest., 2012, 122, 2955-2966.
[68]
Hedblom, A.; Laursen, K.B.; Miftakhova, R.; Sarwar, M.; Anagnostaki, L.; Bredberg, A.; Mongan, N.P.; Gudas, L.J.; Persson, J.L. CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia. Cell Cycle, 2013, 12, 1251-1266.
[69]
Wang, S.; Griffiths, G.; Midgley, C.A.; Barnett, A.L.; Cooper, M.; Grabarek, J.; Ingram, L.; Jackson, W.; Kontopidis, G.; McClue, S.J.; McInnes, C.; McLachlan, J.; Meades, C.; Mezna, M.; Stuart, I.; Thomas, M.P.; Zheleva, D.I.; Lane, D.P.; Jackson, R.C.; Glover, D.M.; Blake, D.G.; Fischer, P.M. Discovery and characterization of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem. Biol., 2010, 17, 1111-1121.
[70]
Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S.Y.; McInnes, C.; Zheleva, D.; Walkinshaw, M.D.; Fischer, P.M. 2-Anilino-4-(thiazol-5-yl) pyrimidine CDK inhibitors: Synthesis, SAR analysis, X-ray crystallography, and biological activity. J. Med. Chem., 2004, 47, 1662-1675.
Related Books
Science of Spices and Culinary Herbs - Latest Laboratory, Pre-clinical, and Clinical Studies
Frontiers in Natural Product Chemistry
Therapeutic Use of Plant Secondary Metabolites
Therapeutic Implications of Natural Bioactive Compounds
Frontiers in Bioactive Compounds
Frontiers in Natural Product Chemistry
Frontiers in Natural Product Chemistry
Science of Spices and Culinary Herbs - Latest Laboratory, Pre-clinical, and Clinical Studies
Frontiers in Natural Product Chemistry
Frontiers in Natural Product Chemistry
Article Metrics
53
10
1